ObsEva SA (NASDAQ:OBSV) Given Average Recommendation of “Hold” by Analysts

Shares of ObsEva SA (NASDAQ:OBSV – Get Rating) have been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $8.33.

Separately, StockNews.com assumed coverage on shares of ObsEva in a research note on Friday. They set a “hold” rating on the stock.

Institutional Investors Weigh In On ObsEva

A number of large investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP acquired a new stake in shares of ObsEva during the 3rd quarter worth about $25,000. Virtu Financial LLC acquired a new stake in shares of ObsEva during the 1st quarter worth about $30,000. Pictet Asset Management SA boosted its stake in shares of ObsEva by 25.8% during the 3rd quarter. Pictet Asset Management SA now owns 371,595 shares of the company’s stock worth $53,000 after purchasing an additional 76,196 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of ObsEva by 33.9% during the 1st quarter. XTX Topco Ltd now owns 79,757 shares of the company’s stock worth $120,000 after purchasing an additional 20,196 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of ObsEva during the 2nd quarter worth about $192,000. 17.52% of the stock is owned by institutional investors and hedge funds.

ObsEva Trading Down 7.8 %

OBSV opened at $0.12 on Friday. The firm’s 50-day moving average price is $0.18 and its 200 day moving average price is $0.17. ObsEva has a twelve month low of $0.08 and a twelve month high of $2.14. The firm has a market capitalization of $9.34 million, a PE ratio of -0.13 and a beta of 0.68.

ObsEva Company Profile

(Get Rating)

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.